AZN icon

AstraZeneca

79.66 USD
-1.31
1.62%
At close Aug 25, 4:00 PM EDT
Pre-market
81.18
+1.52
1.91%
1 day
-1.62%
5 days
0.42%
1 month
9.63%
3 months
12.26%
6 months
5.65%
Year to date
20.92%
1 year
-8.04%
5 years
39.73%
10 years
163.08%
 

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Employees: 94,300

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

147% more call options, than puts

Call options by funds: $508M | Put options by funds: $206M

6% more repeat investments, than reductions

Existing positions increased: 453 | Existing positions reduced: 428

9% less first-time investments, than exits

New positions opened: 96 | Existing positions closed: 106

3% less funds holding

Funds holding: 1,233 [Q1] → 1,193 (-40) [Q2]

9% less capital invested

Capital invested by funds: $37.6B [Q1] → $34.1B (-$3.55B) [Q2]

16.81% less ownership

Funds ownership: 32.59% [Q1] → 15.78% (-16.81%) [Q2]

48% less funds holding in top 10

Funds holding in top 10: 21 [Q1] → 11 (-10) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for AZN.

Financial journalist opinion

Based on 36 articles about AZN published over the past 30 days

Neutral
Business Wire
4 days ago
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service available for the 2025-2026 flu season. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home on a date they choose—no doctor's visit or needle required. The program is the first of its kind to receive FD.
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
Positive
Zacks Investment Research
1 week ago
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
Neutral
PRNewsWire
1 week ago
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
Positive
Seeking Alpha
2 weeks ago
AstraZeneca: Great Portfolio, But Not A Great Price
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
AstraZeneca: Great Portfolio, But Not A Great Price
Negative
Proactive Investors
2 weeks ago
Ex-dividend day weighs heavily on the FTSE this week
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:NWG) and Rolls-Royce Holdings PLC (LSE:RR.). There were 18.3 points collectively shaved off the index as a result of 12 blue-chips going ex-dividend on the day, when investors who purchase shares today are no longer entitled to their latest dividend payouts.
Ex-dividend day weighs heavily on the FTSE this week
Neutral
PRNewsWire
3 weeks ago
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
Neutral
WSJ
3 weeks ago
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Positive
Zacks Investment Research
3 weeks ago
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
Positive
Zacks Investment Research
3 weeks ago
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Positive
CNBC Television
3 weeks ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Charts implemented using Lightweight Charts™